The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study

BACKGROUND: We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication overuse (MO). METHODS: In a 12-week, phase 3 trial, patients with CM were randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberstein, Stephen D., Cohen, Joshua M., Seminerio, Michael J., Yang, Ronghua, Ashina, Sait, Katsarava, Zaza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507645/
https://www.ncbi.nlm.nih.gov/pubmed/32958075
http://dx.doi.org/10.1186/s10194-020-01173-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507645/
https://www.ncbi.nlm.nih.gov/pubmed/32958075
http://dx.doi.org/10.1186/s10194-020-01173-8

Ejemplares similares